• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Indonesia·Healthcare·PRAY.JK
Share

PT Famon Awal Bros Sedaya Tbk Stocks

IDR 660Last Updated 23.06.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

IDR 590.48M

IDR 660
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

PT Famon Awal Bros Sedaya Tbk operates a network of hospitals throughout Indonesia. The company delivers a broad spectrum of specialized medical services, encompassing cardiovascular treatment, orthopedic sports medicine, trauma care, oncology (cancer treatment), neurological and brain health, ophthalmology, maternal and pediatric services, and urology. Additionally, it offers clinical laboratory analysis, in-home care, medical transportation, and digital consultation services, among other diverse healthcare provisions. Founded in 1997 and headquartered in Kemayoran, Indonesia, PT Famon Awal Bros Sedaya Tbk is a subsidiary of PT Famon Obor Maju.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of PRAY.JK is 1200 and suggests 69% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

24.06.2026 10:35

Top Stories This Morning: Asia Recovers After Sell-Off, SpaceX Raises $25 Billion

24.06.2026 09:00

Apollo and Morgan Stanley have once again restricted withdrawals from private credit funds

24.06.2026 08:00

Alibaba has filed a lawsuit against the Pentagon over allegations of ties to the Chinese military

24.06.2026 07:00

Alphabet will be added to the Dow Jones Blue Chip Index. Its stock price has doubled over the past year

24.06.2026 01:47

The boom in the prediction market has prompted Meta to create its own app — NYT

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026